Jideytro positive data for ROS1-positive NSCLC

GSK reports 94% response rate for Jideytro in first-line ROS1-positive lung cancer trial.

What the company is saying

GSK is highlighting strong efficacy and tolerability data for Jideytro (zidesamtinib) in TKI-naïve ROS1-positive non-small cell lung cancer, positioning the drug as a potential first-line treatment. The company frames the 94% objective response rate and 90% 12-month progression-free survival as clinically meaningful, emphasizing durability with 86% of patients still responding at one year. GSK underscores intracranial activity, noting 100% response and 70% complete clearance in patients with measurable brain metastases. Safety is presented as manageable, with low discontinuation (1%) and dose reduction (11%) rates, and most adverse events described as low grade. Hesham Abdullah, GSK’s Global Head of Oncology R&D, and Alexander Drilon, ARROS-1’s principal investigator, both stress the potential for a differentiated first-line profile and the importance of long-term disease control. The announcement is timed to coincide with data presentation at a major oncology conference and supports a planned US regulatory submission in 2026.

What the data suggests

The ARROS-1 phase I/II trial enrolled 94 efficacy-evaluable, TKI-naïve patients with advanced or metastatic ROS1-positive NSCLC. Zidesamtinib achieved a 94% objective response rate (88/94; 95% CI: 87–98) after a median follow-up of 15.2 months, including a 15% complete response rate (14/94). Responses were durable, with 94% of patients still responding at nine months and 86% at 12 months. At 12 months, 90% of patients remained progression-free, though median progression-free survival and duration of response were not reached. Among 10 patients with measurable brain metastases, 100% responded and 70% achieved complete clearance of brain tumors; 78% maintained intracranial response at 12 months. Treatment-related adverse events led to dose reductions in 11% and discontinuation in 1%, with the most common events (≥15%) being peripheral oedema, weight increase, blood creatine phosphokinase increase, dysgeusia, and aspartate aminotransferase increase, mostly low grade. The data are robust for efficacy and safety endpoints, but financial metrics, revenue, or commercial projections are not disclosed.

Analysis

The announcement is largely factual and data-driven, presenting mature clinical trial results for zidesamtinib in ROS1-positive NSCLC, with high response rates and detailed safety outcomes. The only forward-looking claim is the planned supplemental New Drug Application to the US FDA for first-line use, which is a logical next step based on the disclosed data. There is no exaggerated language or overstatement of future commercial impact; the tone is positive but proportionate to the evidence. No financial or profitability metrics are disclosed, so the true_signal cannot exceed weak_positive, but the clinical data is robust and well-supported. The acquisition of Nuvalent, Inc. is mentioned as completed, with no hype around future synergies or financial impact. The benefits of the trial results are expected in the near term, pending regulatory submission and review.

Risk flags

• ●Regulatory risk remains significant, as Jideytro is not yet approved for first-line use anywhere in the world. FDA acceptance and review could identify issues not apparent in the current data, delaying or preventing approval.
• ●The trial is single-arm and non-randomized, which may limit comparability to standard-of-care treatments and could complicate regulatory or payer acceptance if real-world outcomes differ.
• ●Financial impact is unclear, as no revenue, cost, or market size projections are provided. The announcement does not quantify the expected commercial opportunity or address pricing, reimbursement, or competitive dynamics.
• ●Central nervous system efficacy is promising, but the small sample size for patients with measurable brain metastases (n=10) introduces uncertainty about generalizability to broader patient populations.
• ●Long-term safety and durability beyond the current follow-up (median 15.2 months) are not established, and late-emerging adverse events or resistance could affect the risk-benefit profile post-approval.

Bottom line

GSK’s ARROS-1 data for Jideytro in first-line ROS1-positive NSCLC show a 94% response rate and 90% 12-month progression-free survival, with strong intracranial activity and low discontinuation rates. The results support a near-term US regulatory submission, but approval and commercial uptake are not guaranteed. The absence of financial projections or market sizing leaves the revenue impact uncertain, and the single-arm design may challenge payer or regulatory acceptance. Investors should focus on the FDA’s response to the submission, any head-to-head data versus existing therapies, and future disclosures on commercial strategy. The most important takeaway is that Jideytro is now a credible first-line contender in a rare but high-need lung cancer subset, but execution and regulatory hurdles remain.

Announcement summary

(LSE/AIM:GSK) GSK plc announced positive results from the registrational phase I/II ARROS-1 trial evaluating Jideytro (zidesamtinib) in TKI-naïve patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The data, presented at the 2026 World Conference on Lung Cancer in Seoul, South Korea, showed a 94% objective response rate (88/94; 95% CI: 87-98) after a median follow-up of 15.2 months, including a 15% complete response rate (14/94). At 12 months, 90% of patients were progression free, with median progression-free survival (PFS) not yet reached. Responses were durable, with 94% of patients continuing to respond at nine months and 86% at 12 months. Among patients with measurable brain metastases at baseline (n=10), 100% responded to zidesamtinib and 70% achieved complete clearance of detectable brain tumours. At 12 months, 78% maintained an intracranial response, and no central nervous system progression events were observed among patients without brain metastases at baseline. Low rates of treatment discontinuation were observed, with dose reductions in 11% of patients and discontinuation in 1% due to treatment-related adverse events (TRAEs). The most common (≥15%) TRAEs were peripheral oedema, weight increase, blood creatine phosphokinase increase, dysgeusia, and aspartate aminotransferase increase, most of which were low grade. The efficacy-evaluable population included 94 patients, with 27% having received prior chemotherapy and 17% with baseline central nervous system metastases. The global, single-arm, first-in-human phase I/II ARROS-1 study included 532 patients with ROS1-positive NSCLC who received zidesamtinib 100 mg once daily across all lines of therapy, with 183 receiving their first TKI-targeted treatment. GSK plans a supplemental New Drug Application to the US FDA in 2026 to expand the indication for Jideytro to include first-line treatment. Zidesamtinib is not approved anywhere in the world for use as first-line therapy, but in July 2026, the FDA approved it for patients with ROS1-positive NSCLC previously treated with a TKI. Jideytro was part of GSK’s portfolio from the recently completed acquisition of Nuvalent, Inc.

Disagree with this article?